Konsyl Pharmaceuticals Revenue and Competitors

Easton, MD USA

Location

N/A

Total Funding

Health

Industry

Estimated Revenue & Valuation

  • Konsyl Pharmaceuticals's estimated annual revenue is currently $13.1M per year.(i)
  • Konsyl Pharmaceuticals's estimated revenue per employee is $243,000

Employee Data

  • Konsyl Pharmaceuticals has 54 Employees.(i)
  • Konsyl Pharmaceuticals grew their employee count by 13% last year.

Konsyl Pharmaceuticals's People

NameTitleEmail/Phone
1
Director SalesReveal Email/Phone
2
Director SalesReveal Email/Phone
3
Director MarketingReveal Email/Phone
4
General ManagerReveal Email/Phone
5
Brand Marketing ManagerReveal Email/Phone
6
Finance ManagerReveal Email/Phone
7
Konsyl Domestic Sales and Account RepresentativeReveal Email/Phone
8
QA/Sales AdministratorReveal Email/Phone
9
Maintenance MangerReveal Email/Phone
10
BuyerReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$20.8M771%N/AN/A
#2
$7.6M353%N/AN/A
#3
$18.2M757%N/AN/A
#4
$8.6M40-2%N/AN/A
#5
$105M31117%N/AN/A
#6
$65.6M2213%N/AN/A
#7
$8.9M4114%N/AN/A
#8
$6.7M313%N/AN/A
#9
$28.1M1040%N/AN/A
#10
$27.8M1037%N/AN/A
Add Company

What Is Konsyl Pharmaceuticals?

For the past 80 years our products have been widely distributed around the globe in over 40 countries. Our current OTC drug and supplement products are currently available in a variety of retail locations as well as on konsyl.com. The company also manufactures a medical device sold under the brand name Sitzmarks, used for diagnosing patients who suffer from certain digestion maladies. Konsyl is continuing to look to the future with ambitious plans to expand the product portfolio to include various products within the health and wellness market.

keywords:N/A

N/A

Total Funding

54

Number of Employees

$13.1M

Revenue (est)

13%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.7M5517%N/A
#2
$13.4M5522%N/A
#3
N/A5730%N/A
#4
$17.2M5816%N/A
#5
$15.1M607%N/A